{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:25:42Z","timestamp":1789601142640,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.4158\/ep-2018-0444","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T14:00:01Z","timestamp":1552485601000},"page":"589-597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Greater Combined Reductions in Hba1C \u22651.0% and Weight \u22655.0% with Semaglutide Versus Comparators in type 2 Diabetes"],"prefix":"10.1016","volume":"25","author":[{"given":"Helena W.","family":"Rodbard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Bellary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Hramiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Seino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Holm","family":"Damgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurudutt","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe","family":"Zacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita R","family":"Aroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP-2018-0444_bb0010","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/1479164113490765","article-title":"Individualized glycaemic targets and pharmacotherapy in type 2 diabetes","volume":"10","author":"Bailey","year":"2013","journal-title":"Diab Vasc Dis Res"},{"key":"10.4158\/EP-2018-0444_bb0015","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/1479164109341691","article-title":"What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management","volume":"6","author":"Bailey","year":"2009","journal-title":"Diab Vasc Dis Res"},{"key":"10.4158\/EP-2018-0444_bb0020","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"Ryd\u00e9n","year":"2013","journal-title":"Eur Heart J"},{"issue":"suppl 1","key":"10.4158\/EP-2018-0444_bb0025","first-page":"S1","article-title":"Standards of medical care in diabetes-2017","volume":"40","author":"American Diabetes Association","year":"2017","journal-title":"Diabetes Care"},{"key":"10.4158\/EP-2018-0444_bb0030","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2337\/dci15-0012","article-title":"Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"38","author":"Fox","year":"2015","journal-title":"Diabetes Care"},{"key":"10.4158\/EP-2018-0444_bb0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2458-9-88","article-title":"The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis","volume":"9","author":"Guh","year":"2009","journal-title":"BMC Public Health"},{"key":"10.4158\/EP-2018-0444_bb0040","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.106.171016","volume":"113","author":"Poirier","year":"2006","journal-title":"Circulation"},{"key":"10.4158\/EP-2018-0444_bb0045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/oxfordjournals.bmb.a011615","article-title":"Obesity as a disease","volume":"53","author":"Jung","year":"1997","journal-title":"Br Med Bull"},{"key":"10.4158\/EP-2018-0444_bb0050","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.2105\/AJPH.88.12.1814","article-title":"Quality of life in relation to overweight and body fat distribution","volume":"88","author":"Han","year":"1998","journal-title":"Am J Public Health"},{"key":"10.4158\/EP-2018-0444_bb0055","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jand.2015.02.031","article-title":"Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"115","author":"Franz","year":"2015","journal-title":"J Acad Nutr Diet"},{"key":"10.4158\/EP-2018-0444_bb0060","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2337\/dc12-2258","article-title":"The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988\u20132010","volume":"36","author":"Stark Casagrande","year":"2013","journal-title":"Diabetes Care"},{"key":"10.4158\/EP-2018-0444_bb0065","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"issue":"25 suppl 2","key":"10.4158\/EP-2018-0444_bb0070","first-page":"S102","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"10.4158\/EP-2018-0444_bb0075","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"key":"10.4158\/EP-2018-0444_bb0080","unstructured":"National Institute for Clinical ExcellenceType 2 diabetes in adults: management [NG28] 2015 [updated December 2015. NICE clinical guideline]. Available at: http:\/\/www.nice.org.uk\/guidance\/ng28. Accessed January 22, 2019."},{"key":"10.4158\/EP-2018-0444_bb0085","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"10.4158\/EP-2018-0444_bb0090","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s40262-017-0528-2","article-title":"Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment","volume":"56","author":"Marbury","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.4158\/EP-2018-0444_bb0095","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.4158\/EP-2018-0444_bb0100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.4158\/EP-2018-0444_bb0105","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"10.4158\/EP-2018-0444_bb0110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.4158\/EP-2018-0444_bb0115","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomised, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2018-0444_bb0120","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.4158\/EP-2018-0444_bb0125","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2018-0444_bb0130","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(14)70029-4","article-title":"Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial","volume":"2","author":"Diamant","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.4158\/EP-2018-0444_bb0135","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"key":"10.4158\/EP-2018-0444_bb0140","unstructured":"European Medicines AgencyInternational Conference on Harmonisation Guideline for Good Clinical Practice E6(R2) 2009. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002874.pdf. Accessed January 22, 2019."},{"key":"10.4158\/EP-2018-0444_bb0145","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"10.4158\/EP-2018-0444_bb0150","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"key":"10.4158\/EP-2018-0444_bb0155","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP-2018-0444_bb0160","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2017.31","article-title":"Enhanced insulin sensitivity in successful, long-term weight loss maintainers compared with matched controls with no weight loss history","volume":"7","author":"Clamp","year":"2017","journal-title":"Nutr Diabetes"},{"key":"10.4158\/EP-2018-0444_bb0165","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2018-02685","article-title":"Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide","author":"Fonseca","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2018-0444_bb0170","series-title":"Diabetes in America, 3rd ed","first-page":"9","article-title":"Physical and metabolic characteristics of persons with diabetes and prediabetes","author":"Menke","year":"2018"},{"key":"10.4158\/EP-2018-0444_bb0175","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jcjd.2013.03.023","article-title":"Benefits of modest weight loss on the management of type 2 diabetes mellitus","volume":"37","author":"Lau","year":"2013","journal-title":"Can J Diabetes"},{"key":"10.4158\/EP-2018-0444_bb0180","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.4158\/EP-2018-0444_bb0185","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2337\/dc14-1630","article-title":"Weight management in type 2 diabetes: current and emerging approaches to treatment","volume":"38","author":"Van Gaal","year":"2015","journal-title":"Diabetes Care"},{"key":"10.4158\/EP-2018-0444_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2035970X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2035970X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:06:07Z","timestamp":1761516367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2035970X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1530891X2035970X"],"URL":"https:\/\/doi.org\/10.4158\/ep-2018-0444","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Greater Combined Reductions in Hba1C \u22651.0% and Weight \u22655.0% with Semaglutide Versus Comparators in type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP-2018-0444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}